Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Antigens"" wg kryterium: Temat


Tytuł :
Serum hepatitis B core-related antigen as a surrogate marker of hepatitis B e antigen seroconversion in chronic hepatitis B.
Autorzy :
Chi XM; Department of Hepatology, Key Laboratory of Zoonosis Research, Ministry Education, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China.
Wang XM; Department of Hepatology, Key Laboratory of Zoonosis Research, Ministry Education, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China.
Wang ZF; Department of Hepatology, Key Laboratory of Zoonosis Research, Ministry Education, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China.
Wu RH; Department of Hepatology, Key Laboratory of Zoonosis Research, Ministry Education, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China.
Gao XZ; Department of Hepatology, Key Laboratory of Zoonosis Research, Ministry Education, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China.
Xu HQ; Department of Hepatology, Key Laboratory of Zoonosis Research, Ministry Education, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China.
Ding YH; Phase I Clinical Trials Unit, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China.
Niu JQ; Department of Hepatology, Key Laboratory of Zoonosis Research, Ministry Education, The First Hospital of Jilin University, Changchun 130021, Jilin Province, China. .
Pokaż więcej
Źródło :
World journal of gastroenterology [World J Gastroenterol] 2021 Oct 28; Vol. 27 (40), pp. 6927-6938.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Hepatitis B e Antigens*
Hepatitis B, Chronic*/diagnosis
Hepatitis B, Chronic*/drug therapy
Antiviral Agents/therapeutic use ; Biomarkers ; DNA, Viral/therapeutic use ; Hepatitis B Core Antigens ; Hepatitis B Surface Antigens ; Hepatitis B virus/genetics ; Humans ; Seroconversion
Czasopismo naukowe
Tytuł :
Quantitative serum HBV markers in predicting phases of natural history of chronic HBV infection.
Autorzy :
Zhang ZQ; Department of Hepatobiliary Medicine, Shanghai Public Health Clinical Center of Fudan University, China. Electronic address: .
Shi BS; Scientific Research Center, Shanghai Public Health Clinical Center of Fudan University, China. Electronic address: .
Lu W; Department of Hepatobiliary Medicine, Shanghai Public Health Clinical Center of Fudan University, China. Electronic address: .
Huang D; Department of Hepatobiliary Medicine, Shanghai Public Health Clinical Center of Fudan University, China. Electronic address: .
Wang YB; Department of Hepatobiliary Medicine, Shanghai Public Health Clinical Center of Fudan University, China. Electronic address: .
Feng YL; Department of Clinical Pathology, Shanghai Public Health Clinical Center of Fudan University, China. Electronic address: .
Pokaż więcej
Źródło :
Journal of virological methods [J Virol Methods] 2021 Oct; Vol. 296, pp. 114226. Date of Electronic Publication: 2021 Jul 01.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Hepatitis B Core Antigens*
Hepatitis B virus*/genetics
Biomarkers ; DNA, Viral ; Hepatitis B Antibodies ; Hepatitis B Surface Antigens ; Hepatitis B e Antigens ; Humans
Czasopismo naukowe
Tytuł :
Entecavir Plus Pegylated Interferon and Sequential Hepatitis B Virus Vaccination Increases Hepatitis B Surface Antigen Seroclearance: A Randomized Controlled Proof-of-Concept Study.
Autorzy :
Lee JH; Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Lee YB; Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Cho EJ; Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Yu SJ; Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Yoon JH; Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Kim YJ; Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Pokaż więcej
Źródło :
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2021 Nov 02; Vol. 73 (9), pp. e3308-e3316.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Hepatitis B Surface Antigens*
Hepatitis B, Chronic*/drug therapy
Hepatitis B, Chronic*/prevention & control
Antiviral Agents/therapeutic use ; DNA, Viral ; Guanine/analogs & derivatives ; Hepatitis B e Antigens ; Hepatitis B virus/genetics ; Humans ; Polyethylene Glycols/therapeutic use ; Recombinant Proteins/therapeutic use ; Vaccination
Czasopismo naukowe
Tytuł :
PeptiCHIP: A Microfluidic Platform for Tumor Antigen Landscape Identification.
Autorzy :
Feola S; Drug Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014 Helsinki, Finland.
Haapala M; Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland.
Peltonen K; Drug Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014 Helsinki, Finland.
Capasso C; Drug Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014 Helsinki, Finland.
Martins B; Drug Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014 Helsinki, Finland.
Antignani G; Drug Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014 Helsinki, Finland.
Federico A; Faculty of Medicine and Health Technology, Tampere University, Arvo Ylpön katu 34, Tampere 33520, Finland.
Pietiäinen V; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014 Helsinki, Finland.; Institute for Molecular Medicine Finland, FIMM, Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Biomedicum 2U, Tukholmankatu 8, 00290 Helsinki, Finland.
Chiaro J; Drug Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014 Helsinki, Finland.
Feodoroff M; Drug Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014 Helsinki, Finland.; Institute for Molecular Medicine Finland, FIMM, Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Biomedicum 2U, Tukholmankatu 8, 00290 Helsinki, Finland.
Russo S; Drug Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014 Helsinki, Finland.
Rannikko A; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014 Helsinki, Finland.; Department of Urology, Helsinki University and Helsinki University Hospital, Haartmaninkatu 8, 00029 Helsinki, Finland.; Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Haartmaninkatu 8, 00029 Helsinki, Finland.
Fusciello M; Drug Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014 Helsinki, Finland.
Koskela S; Research & Development Finnish Red Cross Blood Service Helsinki, Kivihaantie 7, 00310 Helsinki, Finland.
Partanen J; Research & Development Finnish Red Cross Blood Service Helsinki, Kivihaantie 7, 00310 Helsinki, Finland.
Hamdan F; Drug Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014 Helsinki, Finland.
Tähkä SM; Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland.
Ylösmäki E; Drug Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014 Helsinki, Finland.
Greco D; Faculty of Medicine and Health Technology, Tampere University, Arvo Ylpön katu 34, Tampere 33520, Finland.
Grönholm M; Drug Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014 Helsinki, Finland.
Kekarainen T; Kuopio Center for Gene and Cell Therapy, Microkatu 1S, 70210 Kuopio, Finland.
Eshaghi M; Kuopio Center for Gene and Cell Therapy, Microkatu 1S, 70210 Kuopio, Finland.
Gurvich OL; Kuopio Center for Gene and Cell Therapy, Microkatu 1S, 70210 Kuopio, Finland.
Ylä-Herttuala S; A. I. Virtanen Institute, University of Eastern Finland, Neulaniementie 2, 70211 Kuopio, Finland.
M Branca RM; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Tomtebodavagen 23B, 171 21 Solna, Sweden.
Lehtiö J; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Tomtebodavagen 23B, 171 21 Solna, Sweden.
Sikanen TM; Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland.
Cerullo V; Drug Research Program (DRP), ImmunoViroTherapy Lab (IVT), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland.; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Fabianinkatu 33, 00710 Helsinki, Finland.; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki, Finland.; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014 Helsinki, Finland.; Department of Molecular Medicine and Medical Biotechnology, Naples University 'Federico II', S. Pansini 5, 80131 Naples, Italy.
Pokaż więcej
Źródło :
ACS nano [ACS Nano] 2021 Oct 26; Vol. 15 (10), pp. 15992-16010. Date of Electronic Publication: 2021 Oct 04.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Histocompatibility Antigens Class I*
Microfluidics*
Antigens, Neoplasm ; Humans ; Ligands ; Peptides
Czasopismo naukowe
Tytuł :
Prevention of platelet transfusion refractoriness by platelet antigen gene matching: a systematic review and meta-analysis.
Autorzy :
Wang J; Department of Blood Transfusion, The First Affiliated Hospital of Soochow University, Suzhou, China.
Zhang X; Department of Blood Transfusion, The First Affiliated Hospital of Soochow University, Suzhou, China.
Li Y; Department of Blood Transfusion, The First Affiliated Hospital of Soochow University, Suzhou, China.
Pokaż więcej
Źródło :
Annals of palliative medicine [Ann Palliat Med] 2021 Oct; Vol. 10 (10), pp. 10946-10953.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Antigens, Human Platelet*
Thrombocytopenia*
Blood Platelets ; HLA Antigens ; Humans ; Platelet Transfusion
Czasopismo naukowe
Tytuł :
Peg-interferon alpha add-on Tenofovir disoproxil fumarate achieved more HBsAg loss in HBeAg-positive chronic hepatitis B naïve patients.
Autorzy :
Li J; Department of Infectious Diseases, Research Laboratory of Clinical Virology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Qu L; Department of Infectious Diseases, East Hospital, Tongji University, Shanghai, China.
Sun X; Liver Disease Department, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Liu Y; Department of Infectious Diseases, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Gong Q; Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yu D; Department of Infectious Diseases, Research Laboratory of Clinical Virology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhang D; Department of Infectious Diseases, Research Laboratory of Clinical Virology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jiang J; Department of Infectious Diseases, Research Laboratory of Clinical Virology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Chen J; Department of Infectious Diseases, Research Laboratory of Clinical Virology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Wei D; Department of Infectious Diseases, Research Laboratory of Clinical Virology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Han Y; Department of Infectious Diseases, Research Laboratory of Clinical Virology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Gao Y; Liver Disease Department, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Zhang Q; Department of Infectious Diseases, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
She W; Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, China.
Chen L; Department of Hepatic Diseases, Shanghai Public Health Clinical Center, Shanghai, China.
Zhang J; Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.
Zhang X; Department of Infectious Diseases, Research Laboratory of Clinical Virology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.; Sino-French Research Centre for Life Sciences and Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Pokaż więcej
Źródło :
Journal of viral hepatitis [J Viral Hepat] 2021 Oct; Vol. 28 (10), pp. 1381-1391. Date of Electronic Publication: 2021 Jul 14.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Hepatitis B Surface Antigens*
Hepatitis B, Chronic*/drug therapy
Antiviral Agents/therapeutic use ; DNA, Viral ; Drug Therapy, Combination ; Hepatitis B e Antigens ; Hepatitis B virus/genetics ; Humans ; Interferon-alpha/therapeutic use ; Polyethylene Glycols/therapeutic use ; Prospective Studies ; Tenofovir/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Editorial: only steps away from primetime? Hepatitis B virus RNA as a routine marker to guide HBV treatment decisions-authors' reply.
Autorzy :
Xia M; State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Chi H; Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands.
Janssen HLA; Toronto Centre of Liver Disease, University Health Network, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.
Peng J; State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Pokaż więcej
Źródło :
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2021 Oct; Vol. 54 (7), pp. 972-973.
Typ publikacji :
Editorial; Comment
MeSH Terms :
Hepatitis B e Antigens*
Hepatitis B virus*/genetics
Biomarkers ; Hepatitis B Surface Antigens ; Humans ; RNA
Opinia redakcyjna
Tytuł :
Allotype-Specific Glycosylation and Cellular Localization of Human Leukocyte Antigen Class I Proteins.
Autorzy :
Hoek M; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, Utrecht 3584 CH, The Netherlands.; Netherlands Proteomics Center, Padualaan 8, Utrecht 3584 CH, The Netherlands.
Demmers LC; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, Utrecht 3584 CH, The Netherlands.; Netherlands Proteomics Center, Padualaan 8, Utrecht 3584 CH, The Netherlands.
Wu W; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, Utrecht 3584 CH, The Netherlands.; Netherlands Proteomics Center, Padualaan 8, Utrecht 3584 CH, The Netherlands.
Heck AJR; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, Utrecht 3584 CH, The Netherlands.; Netherlands Proteomics Center, Padualaan 8, Utrecht 3584 CH, The Netherlands.
Pokaż więcej
Źródło :
Journal of proteome research [J Proteome Res] 2021 Sep 03; Vol. 20 (9), pp. 4518-4528. Date of Electronic Publication: 2021 Aug 20.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antigen Presentation*
Histocompatibility Antigens Class I*
Cell Membrane ; Glycosylation ; Golgi Apparatus ; HLA Antigens ; Histocompatibility Antigens Class II ; Humans
Czasopismo naukowe
Tytuł :
Comparison of HBV-DNA and HBeAg as antiviral therapeutic indicators among HBV-infected pregnant women: a systematic review and meta-analysis.
Autorzy :
Liu X; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Chen C; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jiang D; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Cui D; Department of Blood Transfusion, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yan D; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Zhou Y; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Ding C; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Lan L; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Huang C; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Zhang X; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Li L; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Zhu C; Department of Laboratory Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Yang S; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Pokaż więcej
Źródło :
Annals of palliative medicine [Ann Palliat Med] 2021 Sep; Vol. 10 (9), pp. 9362-9371. Date of Electronic Publication: 2021 Aug 06.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Hepatitis B e Antigens*
Pregnancy Complications, Infectious*/drug therapy
Antiviral Agents/therapeutic use ; DNA, Viral ; Female ; Hepatitis B Surface Antigens ; Hepatitis B virus/genetics ; Humans ; Infant ; Infectious Disease Transmission, Vertical/prevention & control ; Pregnancy ; Pregnant Women
Czasopismo naukowe
Tytuł :
Prognostic impact of soluble CD163 in patients with diffuse large B-cell lymphoma.
Autorzy :
Vajavaara H; Research Program Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki.
Ekeblad F; Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala.
Holte H; Department of Oncology and KG Jebsen center for B-cell malignancies, Oslo University Hospital, Oslo.
Jorgensen J; Department of Hematology, Aarhus University Hospital, Aarhus.
Leivonen SK; Research Program Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki.
Berglund M; Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala.
Kamper P; Department of Hematology, Aarhus University Hospital, Aarhus.
Moller HJ; Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus.
D'Amore F; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus.
Molin D; Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala.
Enblad G; Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala.
Ludvigsen M; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus.
Glimelius I; Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden; Department of Medicine, division of clinical epidemiology, Karolinska Institutet, Solna. .
Leppa S; Research Program Unit, Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki. .
Pokaż więcej
Źródło :
Haematologica [Haematologica] 2021 Sep 01; Vol. 106 (9), pp. 2502-2506. Date of Electronic Publication: 2021 Sep 01.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Antigens, CD*
Lymphoma, Large B-Cell, Diffuse*/diagnosis
Lymphoma, Large B-Cell, Diffuse*/drug therapy
Antigens, Differentiation, Myelomonocytic ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Humans ; Prognosis ; Receptors, Cell Surface
Raport
Tytuł :
Virological and immunological predictors of long term outcomes of peginterferon alfa-2a therapy for HBeAg-negative chronic hepatitis B.
Autorzy :
Lee IC; Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan.
Su CW; Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan.
Lan KH; Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Pharmacology, National Yang-Ming University School of Medicine, Taipei, Taiwan.
Wang YJ; Health Care and Services Center, Taipei Veterans General Hospital, Taipei, Taiwan.
Lee KC; Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan.
Lin HC; Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan.
Hou MC; Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan.
Huang YH; Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan; Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan. Electronic address: .
Pokaż więcej
Źródło :
Journal of the Formosan Medical Association = Taiwan yi zhi [J Formos Med Assoc] 2021 Sep; Vol. 120 (9), pp. 1676-1685. Date of Electronic Publication: 2020 Dec 16.
Typ publikacji :
Journal Article
MeSH Terms :
Hepatitis B e Antigens*
Hepatitis B, Chronic*/drug therapy
Antiviral Agents/therapeutic use ; DNA, Viral ; Hepatitis B Surface Antigens ; Humans ; Interferon-alpha ; Leukocytes, Mononuclear ; Polyethylene Glycols/therapeutic use ; Recombinant Proteins/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Tytuł :
The Cromer blood group system: an update.
Autorzy :
Storry JR; Immunohematology, Clinical Immunology and Transfusion Medicine, Department of Laboratory Medicine, Office for Medical Services , Akutgatan 8, SE-22185, Lund , Sweden.
Lomas-Francis C; Immunohematology, Clinical Immunology and Transfusion Medicine, Department of Laboratory Medicine, Office for Medical Services , Akutgatan 8, SE-22185, Lund , Sweden.
Pokaż więcej
Źródło :
Immunohematology [Immunohematology] 2021 Sep; Vol. 37 (3), pp. 118-121.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Blood Group Antigens*/genetics
CD55 Antigens/genetics ; Humans ; Phenotype
Czasopismo naukowe
Tytuł :
HLA class II immunopeptidomics reveals that co-inherited HLA-allotypes within an extended haplotype can improve proteome coverage for immunosurveillance.
Autorzy :
Ramarathinam SH; Department of Biochemistry and Molecular Biology and Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Ho BK; Department of Biochemistry and Molecular Biology and Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Dudek NL; Department of Biochemistry and Molecular Biology and Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Purcell AW; Department of Biochemistry and Molecular Biology and Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Pokaż więcej
Źródło :
Proteomics [Proteomics] 2021 Sep; Vol. 21 (17-18), pp. e2000160. Date of Electronic Publication: 2021 Aug 17.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
HLA-DQ Antigens*/genetics
Proteome*
Chromatography, Liquid ; Haplotypes ; Histocompatibility Antigens Class II ; Humans ; Monitoring, Immunologic ; Tandem Mass Spectrometry
Czasopismo naukowe
Tytuł :
Associations of immune cell homing gene signatures and infiltrates of lymphocyte subsets in human melanomas: discordance with CD163 myeloid cell infiltrates.
Autorzy :
Kwak M; Department of Surgery, University of Virginia, P.O. Box 800709, Charlottesville, VA, 22908-0709, USA.; Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA.
Erdag G; Department of Surgery, University of Virginia, P.O. Box 800709, Charlottesville, VA, 22908-0709, USA.
Leick KM; Department of Surgery, University of Virginia, P.O. Box 800709, Charlottesville, VA, 22908-0709, USA.
Bekiranov S; Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA, USA.
Engelhard VH; Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA.
Slingluff CL; Department of Surgery, University of Virginia, P.O. Box 800709, Charlottesville, VA, 22908-0709, USA. .; Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA. .
Pokaż więcej
Źródło :
Journal of translational medicine [J Transl Med] 2021 Aug 28; Vol. 19 (1), pp. 371. Date of Electronic Publication: 2021 Aug 28.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antigens, CD*/genetics
Melanoma*/genetics
Antigens, Differentiation, Myelomonocytic ; Humans ; Lymphocyte Subsets ; Macrophages ; Receptors, Cell Surface ; Tumor Microenvironment
Czasopismo naukowe
Tytuł :
Reply letter regarding seroconversion of hepatitis B surface antigen in a successful long-term immune cohort.
Autorzy :
Zheng Z; Department of Epidemiology and Statistic, School of Public Health, Guangxi Medical University, Nanning, China.; Guangxi Key Laboratory for the Prevention and Control of Viral Hepatitis, Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control, Nanning, China.
Zeng QL; Department of Epidemiology and Statistic, School of Public Health, Guangxi Medical University, Nanning, China.; Guangxi Key Laboratory for the Prevention and Control of Viral Hepatitis, Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control, Nanning, China.
Zhou YH; Department of Epidemiology and Statistic, School of Public Health, Guangxi Medical University, Nanning, China.; Guangxi Key Laboratory for the Prevention and Control of Viral Hepatitis, Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control, Nanning, China.
Pokaż więcej
Źródło :
Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2021 Aug 03; Vol. 17 (8), pp. 2775-2776. Date of Electronic Publication: 2021 Apr 14.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Hepatitis B Surface Antigens*
Hepatitis B, Chronic*/therapy
Cohort Studies ; Hepatitis B e Antigens ; Humans ; Seroconversion
Czasopismo naukowe
Tytuł :
Hepatitis B surface antigen kinetics after discontinuation of and retreatment with oral antivirals in non-cirrhotic HBeAg-positive chronic hepatitis B.
Autorzy :
Chen H; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Guangzhou, China.
Ding X; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Guangzhou, China.
Liao G; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Guangzhou, China.
Xia M; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Guangzhou, China.
Ren Z; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Guangzhou, China.
Fan R; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Guangzhou, China.
Peng J; Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Guangzhou, China.
Pokaż więcej
Źródło :
Journal of viral hepatitis [J Viral Hepat] 2021 Aug; Vol. 28 (8), pp. 1121-1129. Date of Electronic Publication: 2021 May 03.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Hepatitis B Surface Antigens*
Hepatitis B, Chronic*/drug therapy
Antiviral Agents/therapeutic use ; Hepatitis B e Antigens ; Hepatitis B virus ; Humans ; Kinetics ; Prospective Studies ; Recurrence ; Retreatment ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Evidence of nucleos(t)ide analogue (NUC) therapy in HBV DNA negative decompensated cirrhosis.
Autorzy :
Alam S; Bangabandhu Sheikh Mujib Medical University, Shahbag, Dhaka, 1000, Bangladesh. .
Khan MAS; Infectious Disease Hospital, Dhaka, Bangladesh.
Khan M; The Liver Center, Dhaka, 1209, Bangladesh.
Pokaż więcej
Źródło :
Hepatology international [Hepatol Int] 2021 Aug; Vol. 15 (4), pp. 1028-1029. Date of Electronic Publication: 2021 Jul 16.
Typ publikacji :
Letter
MeSH Terms :
DNA, Viral*
Hepatitis B e Antigens*
Antiviral Agents/therapeutic use ; Hepatitis B Surface Antigens ; Hepatitis B virus/genetics ; Humans ; Liver Cirrhosis/drug therapy
Opinia redakcyjna
Tytuł :
The role of quantitative HBsAg in the natural history of e antigen-negative chronic hepatitis B: A Tunisian prospective study.
Autorzy :
Baklouti R; Faculty of medicine of Monastir, Department of gastroenterology, Fattouma Bourguiba Hospital, Monastir, Tunisia. Electronic address: .
Gueddiche A; Faculty of medicine of Monastir, Department of gastroenterology, Fattouma Bourguiba Hospital, Monastir, Tunisia.
Ben Abdelwahed M; Faculty of medicine of Monastir, Department of gastroenterology, Fattouma Bourguiba Hospital, Monastir, Tunisia.
Aissaoui F; Faculty of medicine of Monastir, Department of gastroenterology, Fattouma Bourguiba Hospital, Monastir, Tunisia.
Zakhama M; Faculty of medicine of Monastir, Department of gastroenterology, Fattouma Bourguiba Hospital, Monastir, Tunisia.
Bouhlel W; Faculty of medicine of Monastir, Department of gastroenterology, Fattouma Bourguiba Hospital, Monastir, Tunisia.
Sriha A; Faculty of medicine of Monastir, Department of community medicine, Fattouma Bourguiba Hospital, Monastir, Tunisia.
Kooli I; Faculty of medicine of Monastir, Department of infectiology, Fattouma Bourguiba Hospital, Monastir, Tunisia.
Sallem OK; Faculty of medicine of Monastir, Department of gastroenterology, Fattouma Bourguiba Hospital, Monastir, Tunisia.
Argoubi A; Faculty of medicine of Monastir, Department of virology, Fattouma Bourguiba Hospital, Monastir, Tunisia.
Hichem LM; Faculty of medicine of Monastir, Department of gastroenterology, Fattouma Bourguiba Hospital, Monastir, Tunisia.
Ben Chaabane N; Faculty of medicine of Monastir, Department of gastroenterology, Fattouma Bourguiba Hospital, Monastir, Tunisia.
Safer L; Faculty of medicine of Monastir, Department of gastroenterology, Fattouma Bourguiba Hospital, Monastir, Tunisia.
Pokaż więcej
Źródło :
Infectious diseases now [Infect Dis Now] 2021 Aug; Vol. 51 (5), pp. 464-469. Date of Electronic Publication: 2020 Dec 30.
Typ publikacji :
Journal Article
MeSH Terms :
Hepatitis B e Antigens*
Hepatitis B, Chronic*/diagnosis
Carrier State/diagnosis ; DNA, Viral ; Hepatitis B Surface Antigens ; Hepatitis B virus/genetics ; Humans ; Prospective Studies
Czasopismo naukowe
Tytuł :
[Early reduction of serum RANTES can predict HBsAg clearance in patients with chronic hepatitis B treated with nucleos(t)ide analogues combined with peginterferon alpha].
Autorzy :
Jia R; Medical School of Chinese PLA, Beijing 100853, China Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
Wang WX; Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China Peking University 302 Clinical Medical School, Beijing 100039, China.
Gao YY; Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
Luan JQ; Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
Qiao F; Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
Liu JY; Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
Yuan JH; Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
Cheng YQ; Department of Geriatric Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China.
Wang FS; Medical School of Chinese PLA, Beijing 100853, China Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China Peking University 302 Clinical Medical School, Beijing 100039, China.
Fu JL; Medical School of Chinese PLA, Beijing 100853, China Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China Peking University 302 Clinical Medical School, Beijing 100039, China.
Pokaż więcej
Źródło :
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology [Zhonghua Gan Zang Bing Za Zhi] 2021 Jul 20; Vol. 29 (7), pp. 666-672.
Typ publikacji :
Journal Article
MeSH Terms :
Hepatitis B Surface Antigens*
Hepatitis B, Chronic*/drug therapy
Antiviral Agents/therapeutic use ; Chemokine CCL5/therapeutic use ; DNA, Viral ; Hepatitis B e Antigens ; Hepatitis B virus/genetics ; Humans ; Interferon-alpha/therapeutic use ; Polyethylene Glycols/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Tytuł :
[Quantitative hepatitis B core antibody levels can be used as a predictive index of HBsAg clearance].
Autorzy :
Lin X; Fist Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Wang XX; Fist Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Song AX; Fist Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Lu JF; Fist Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Liu YL; Fist Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Jin Y; Fist Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Cao ZH; Fist Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Ma LN; Fist Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Zheng YY; Fist Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Chen XY; Fist Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.
Pokaż więcej
Źródło :
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology [Zhonghua Gan Zang Bing Za Zhi] 2021 Jul 20; Vol. 29 (7), pp. 673-678.
Typ publikacji :
Journal Article
MeSH Terms :
Hepatitis B Surface Antigens*
Hepatitis B, Chronic*/drug therapy
Alanine Transaminase ; Antiviral Agents/therapeutic use ; DNA, Viral ; Hepatitis B Antibodies ; Hepatitis B e Antigens ; Hepatitis B virus/genetics ; Humans ; Treatment Outcome
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies